FDA Publishes Paper Detailing Actions It Intends to Take Regarding the Uses of AI Across the Medical Product Life Cycle

Artificial intelligence or AI isn’t going anywhere, and the FDA is the latest agency to recognize its potential to revolutionize healthcare by advancing medical product development, improving patient care, and expanding the capabilities of healthcare practitioners in its new paper, “Artificial Intelligence and Medical Products: How CBER, CDER, CDRH, and OCP are Working Together.”…
By: Nelson Mullins Riley & Scarborough LLP
Previous Story

AI Regulation on the Move: EU Leads with AI Act as U.S. States Forge Their Own Paths

Next Story

CryptoLink – February 2024 Updates